glp-1 amgen The next phase of the obesity drug race ADA: Amgen talks Repatha, GLP-1
Description
[DOI] [PubMed] [Google Scholar] 126.Harrison S.A., Loomba R., Dubourg J., Ratziu V., Noureddin M
Read Time: 16 min read Ozempic and other GLP-1 drugs have changed the treatment landscape for diabetes and obesity
The FDA makes the data publicly available, enabling drug companies, clinicians and researchers to conduct their own analyses
Endocrinol Diabetes Metab Case Rep
, Niccum, M
doi: 10.1111/IJCP.12361 113 HeLWangJPingFYangNHuangJLiYet al
